ACT Capital Management Invests $8 Million in TG Therapeutics Despite 30% Stock Decline
核心洞察
ACT Capital Management (搜索) established a new $8 million position in TG Therapeutics (搜索), acquiring 268,875 shares despite the biotech's 30% stock decline over the past year.
TG Therapeutics (搜索)' multiple sclerosis drug BRIUMVI generated approximately $606.9 million in product sales in 2025, nearly doubling year-over-year and driving total revenue to $616.3 million.
The company projects $875-900 million in total global revenue for 2026, driven by continued BRIUMVI adoption and international expansion efforts.
ACT Capital Management (搜索) disclosed a significant new investment in TG Therapeutics (搜索) (NASDAQ: TGTX) on February 17, 2026, acquiring 268,875 shares valued at $8,015,164 despite the biotech company's challenging stock performance over the past year. The investment comes as TG Therapeutics trades at $28.58 per share, down 30% year-over-year while the S&P 500 gained approximately 18% during the same period.
Strong Commercial Performance Drives Investment Interest
The investment appears strategically timed as TG Therapeutics (搜索) demonstrates robust commercial momentum with its multiple sclerosis treatment BRIUMVI. Product sales reached approximately $606.9 million in 2025, nearly doubling from the previous year and establishing the drug as the core of the company's business model. The therapy generated $182.7 million in U.S. revenue during the fourth quarter alone, reflecting accelerating adoption among neurologists treating relapsing forms of multiple sclerosis.
Total annual revenue for TG Therapeutics (搜索) reached $616.3 million in 2025, with the company reporting net income of $447.2 million on a trailing twelve-month basis. The strong financial performance underscores BRIUMVI's rapid market penetration and commercial viability in the competitive multiple sclerosis therapeutic landscape.
Portfolio Strategy and Market Position
The TG Therapeutics (搜索) position represents 6.5% of ACT Capital Management (搜索)'s $123.67 million in reportable U.S. equity assets as of December 31, 2025, making it the fund's fifth-largest holding. The investment aligns with ACT Capital's broader healthcare and biotech allocation strategy, which includes positions in Krystal Biotech and Abivax, suggesting a focused approach on innovative drug developers with clinical and regulatory risk profiles.
TG Therapeutics (搜索) operates as a commercial-stage biopharmaceutical company specializing in therapies for hematologic cancers and autoimmune disorders. The company's revenue streams derive primarily from proprietary pharmaceutical product sales and licensing agreements, serving healthcare providers and patients across oncology and immunology markets through monoclonal antibodies and targeted small molecules.
Forward Guidance and Growth Projections
Looking ahead to 2026, TG Therapeutics (搜索) projects total global revenue of approximately $875-900 million, driven largely by continued BRIUMVI adoption and expanding international commercialization efforts. The guidance represents substantial growth expectations from the current revenue base, though previous guidance disappointments have contributed to investor skepticism reflected in the stock's underperformance.
The company maintains a market capitalization of $4.6 billion, positioning it as a mid-cap player in the biotechnology sector. With its focus on novel mechanisms of action and differentiated clinical profiles, TG Therapeutics (搜索) aims to expand its market presence through both proprietary product launches and strategic collaborative agreements, leveraging its growing commercial footprint to address unmet medical needs in its target therapeutic areas.